A Phase 3 interventional study of Alendronate and Placebo in Osteoporosis, sponsored by Evangelisches Krankenhaus Lutherhaus gGmbH. Terminated at 1 site in Germany. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-02-12.
Sponsored by Evangelisches Krankenhaus Lutherhaus gGmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing alendronate in Osteoporosis — 2 open to participants now, 4 under way, none of them phase 3. Alendronate · Osteoporosis.
Among the 51 studies testing alendronate in Osteoporosis, this one is the 3rd largest by enrollment, is one of 2 that started in 2012, is one of 12 in phase 3, and was the 34th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →2 of the 51 studies testing alendronate in Osteoporosis are open now, in 2 countries. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Women only
Paul F Netzel · Sites in United States
Ages 45+ · Women only
By country, each count listing its studies:
Alendronate: first FDA approval 1995 (FOSAMAX), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 15 · Phase 4 17
First in 1997; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 436 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 60 across the 51 interventional studies. Of the 42 that completed or were terminated, 18 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 51 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Evangelisches Krankenhaus Lutherhaus gGmbH as lead sponsor.
Evangelisches Krankenhaus Lutherhaus gGmbH has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing alendronate in Osteoporosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05151484Madhumathi RaoNovel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 51 studies testing alendronate in Osteoporosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of bisphosphonates in long term treatment of osteoporosis.
Is a continued treatment with alendronate for another two years after a preceding therapy with bisphosphonates of at least four years able to reduce the incidence of new osteoporotic fractures in patients at high fracture risk compared to a therapy-free interval?
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Alendronate
Drug: Placebo
70 mg per week
Also known as: Fosamax
1 pill per week
Number of New Osteoporotic Fractures
Number of new osteoporotic fractures. All fractures which occurred without high impact trauma (i.e. atraumatically, minor accidents and falls from standing height and lower) were regarded as osteoporotic fractures, except for fractures of fingers, face, skull and toes.
Time frame: From baseline to study termination (mean duration 5.6 months)
Mortality
Number of deaths
Time frame: From baseline to study termination (mean duration 5.6 months)
Combination of New Osteoporotic Fractures and Deaths
Number of participants with a new osteoporotic fracture or death
Time frame: From baseline to study termination (mean duration 5.6 months)
The study was early terminated due to a low recruitment rate
| Milestone | Placebo | Alendronate |
|---|---|---|
| Started | 221 | 215 |
| Safety analysis set | 197 | 188 |
| Completed | 0 | 0 |
| Not completed | 221 | 215 |
Number of new osteoporotic fractures. All fractures which occurred without high impact trauma (i.e. atraumatically, minor accidents and falls from standing height and lower) were regarded as osteoporotic fractures, except for fractures of fingers, face, skull and toes.
| osteoporotic fractures | Placebo | Alendronate |
|---|---|---|
| Number of New Osteoporotic Fractures | 5 | 5 |
Number of deaths
| Participants | Placebo | Alendronate |
|---|---|---|
| Mortality | 2 | 0 |
Number of participants with a new osteoporotic fracture or death
| Participants | Placebo | Alendronate |
|---|---|---|
| Combination of New Osteoporotic Fractures and Deaths | 7 | 5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 38/197 (19.3%) | 113/197 (57.4%) |
| Alendronate | — | 31/188 (16.5%) | 94/188 (50%) |
| Event | Placebo | Alendronate |
|---|---|---|
| Fractured sacrumInjury, poisoning and procedural complications | 0/197 | 2/188 |
| Sternal fractureInjury, poisoning and procedural complications | 0/197 | 2/188 |
| Transient ischaemic attackNervous system disorders | 1/197 | 2/188 |
| Salpingo-oophorectomySurgical and medical procedures | 0/197 | 2/188 |
| HypertensionVascular disorders | 1/197 | 2/188 |
| Cardiac failureCardiac disorders | 2/197 | 1/188 |
| Abdominal pain upperGastrointestinal disorders | 2/197 | 0/188 |
| Pelvic fractureInjury, poisoning and procedural complications | 2/197 | 1/188 |
| Knee arthroplastySurgical and medical procedures | 2/197 | 0/188 |
| MyocarditisCardiac disorders | 0/197 | 1/188 |
| Event | Placebo | Alendronate |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 57/197 | 44/188 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 39/197 | 27/188 |
| DizzinessNervous system disorders | 38/197 | 22/188 |
| FatigueGeneral disorders | 30/197 | 27/188 |
| HyperhidrosisGeneral disorders | 30/197 | 21/188 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 28/197 | 14/188 |
| HeadacheNervous system disorders | 22/197 | 25/188 |
| CoughRespiratory, thoracic and mediastinal disorders | 24/197 | 14/188 |
| Abdominal pain upperGastrointestinal disorders | 23/197 | 15/188 |
| ConstipationGastrointestinal disorders | 23/197 | 11/188 |
| Age, Continuous(Years) | Placebo | Alendronate | Total |
|---|---|---|---|
| Mean | 75.3 ± 6.9 | 74.3 ± 7.1 | 74.8 ± 7.0 |
| Sex: Female, Male(Participants) | Placebo | Alendronate | Total |
|---|---|---|---|
| Female | 194 | 203 | 397 |
| Male | 27 | 12 | 39 |
| Region of Enrollment(Participants) | Placebo | Alendronate | Total |
|---|---|---|---|
| Germany | 221 | 215 | 436 |
Ran from Feb 2012 to primary completion in Mar 2013, 13 months.
Results were first posted in Jan 2019, 5 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alendronate